Radiopharmaceutical firm Jubilant DraxImage is in the hot seat after hiking the price of two commonly used radiotracers, with the price of one increasing more than 2,000 percent.
The company increased the prices of macroaggregated albumin (MAA) and diethylenetriamine pentaacetate (DTPA), which are used for ventilation/perfusion (V/Q) scans, most often used to help diagnose or rule out a pulmonary embolism, or a blockage of an artery in the lungs, often by a blood clot.
Please click here for the full article.
